Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CATX NYSE:INFU NYSE:NSPR NASDAQ:NVCN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCATXPerspective Therapeutics$3.68+3.4%$3.79$1.60▼$16.55$273.29M1.17940,145 shs579,561 shsINFUInfuSystem$9.57-0.4%$6.79$4.61▼$9.97$196.29M1.81168,396 shs167,703 shsNSPRInspireMD$2.38+0.4%$2.42$1.99▼$3.80$99.30M0.6100,874 shs59,161 shsNVCNNeovasc$30.03$29.69$4.59▼$30.07$82.28M1.756,993 shs1 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCATXPerspective Therapeutics+3.37%+1.94%-15.40%+53.97%-75.89%INFUInfuSystem-0.42%-0.62%+60.57%+76.89%+38.70%NSPRInspireMD+0.42%-4.80%-4.03%-5.93%-16.49%NVCNNeovasc0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCATXPerspective Therapeutics1.7759 of 5 stars3.61.00.00.02.60.80.0INFUInfuSystem3.6519 of 5 stars2.05.00.00.03.34.21.9NSPRInspireMD4.0482 of 5 stars3.55.00.00.03.34.20.6NVCNNeovascN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCATXPerspective Therapeutics 3.18Buy$12.56241.18% UpsideINFUInfuSystem 4.00Strong Buy$12.5030.62% UpsideNSPRInspireMD 3.00Buy$4.5089.08% UpsideNVCNNeovasc 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NVCN, CATX, INFU, and NSPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.007/21/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/12/2025CATXPerspective TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/23/2025CATXPerspective TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $12.006/23/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.006/3/2025CATXPerspective TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.00(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCATXPerspective TherapeuticsN/AN/AN/AN/A$2.67 per shareN/AINFUInfuSystem$139.89M1.40$0.75 per share12.79$2.47 per share3.87NSPRInspireMD$7.07M14.05N/AN/A$1.83 per share1.30NVCNNeovasc$3.81M21.60N/AN/A$5.77 per share5.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%11/11/2025 (Estimated)INFUInfuSystem$870K$0.23159.5330.87N/A1.12%2.78%1.41%N/ANSPRInspireMD-$19.92M-$0.83N/AN/AN/A-413.96%-69.42%-57.68%N/ANVCNNeovasc-$41.20M-$15.08N/A∞N/A-1,082.92%-127.25%-80.31%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCATXPerspective TherapeuticsN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ANVCNNeovascN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCATXPerspective TherapeuticsN/A9.609.60INFUInfuSystem0.501.981.59NSPRInspireMDN/A6.396.05NVCNNeovasc0.802.962.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCATXPerspective Therapeutics54.66%INFUInfuSystem71.13%NSPRInspireMD44.78%NVCNNeovasc1.64%Insider OwnershipCompanyInsider OwnershipCATXPerspective Therapeutics3.72%INFUInfuSystem11.40%NSPRInspireMD34.06%NVCNNeovascN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCATXPerspective Therapeutics7074.26 million65.21 millionOptionableINFUInfuSystem41020.43 million19.10 millionOptionableNSPRInspireMD5041.72 million18.33 millionOptionableNVCNNeovasc492.74 millionN/ANot OptionableNVCN, CATX, INFU, and NSPR HeadlinesRecent News About These CompaniesTop Small-Cap Stocks for May 2023 - InvestopediaMay 13, 2023 | news.google.comNFDA accepts application for Roche's Vabysmo for the - GlobeNewswireMay 9, 2023 | news.google.comNNew treatment option opens avenues in geographic atrophy - HealioMay 8, 2023 | news.google.comNPachychoroid neovasculopathy has clinical properties that differ ... - Nature.comMay 8, 2023 | news.google.comNThe NOD audit provides data and insights for the management for ... - Modern RetinaMay 8, 2023 | news.google.comNShockwave Medical Reports First Quarter 2023 Financial Results - GlobeNewswireMay 8, 2023 | news.google.comNHeart valve repair and replacement devices market size to grow by ... - BenzingaMay 5, 2023 | news.google.comNASCRS: Prediction of imminent conversion to neovascular AMD ... - Optometry TimesMay 5, 2023 | news.google.comNFaricimab in Treatment-Resistant nARMD | OPTH - Dove Medical PressMay 4, 2023 | news.google.comNRestoring vision through retinal ganglion cell repopulation - Ophthalmology Times EuropeMay 4, 2023 | news.google.comNSTAR Trial: Surgery Not Superior to Pneumatic Displacement for ... - MD MagazineMay 4, 2023 | news.google.comNThe NOD audit: Insights into the current state of management for ... - Nature.comMay 4, 2023 | news.google.comNOn the horizon: Treatments for both forms of AMD - Ophthalmology Times EuropeMay 3, 2023 | news.google.comNBiosimilar Ranibizumab Displays Comparable Safety, Efficacy to ... - The Center for BiosimilarsApril 28, 2023 | news.google.comNReal World Evidence Supporting GA Therapy Management Strategies - AJMC.com Managed Markets NetworkApril 28, 2023 | news.google.comNLow-vision services improve vision, quality of life in patients with ... - HealioApril 28, 2023 | news.google.comNNew Vabysmo data suggest greater retinal drying versus aflibercept ... - GlobeNewswireApril 25, 2023 | news.google.comNNew treatment tackles both forms of AMD - Ophthalmology TimesApril 25, 2023 | news.google.comNPrice Variation in Economic Evaluations of Infliximab Could ... - The Center for BiosimilarsApril 25, 2023 | news.google.comN1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - Yahoo FinanceApril 25, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVCN, CATX, INFU, and NSPR Company DescriptionsPerspective Therapeutics NYSE:CATX$3.68 +0.12 (+3.37%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$3.60 -0.08 (-2.20%) As of 08/22/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.InfuSystem NYSE:INFU$9.57 -0.04 (-0.42%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$9.57 0.00 (0.00%) As of 08/22/2025 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.InspireMD NYSE:NSPR$2.38 +0.01 (+0.42%) Closing price 08/22/2025 03:59 PM EasternExtended Trading$2.43 +0.05 (+2.10%) As of 08/22/2025 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Neovasc NASDAQ:NVCNNeovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot 3 Reasons Salesforce Is a Bargain Right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access